224 related articles for article (PubMed ID: 34139345)
21. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
22. Integrated therapy of kidney cancer.
Longo R; D'Andrea MR; Sarmiento R; Salerno F; Gasparini G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi141-8. PubMed ID: 17591809
[TBL] [Abstract][Full Text] [Related]
23. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Hong DS; Gordon MS; Samlowski WE; Kurzrock R; Tannir N; Friedland D; Mendelson DS; Vogelzang NJ; Rasmussen E; Wu BM; Bass MB; Zhong ZD; Friberg G; Appleman LJ
Clin Genitourin Cancer; 2014 Jun; 12(3):167-177.e2. PubMed ID: 24365125
[TBL] [Abstract][Full Text] [Related]
24. [Value of targeted therapies for renal cell cancer].
Merseburger AS; Kuczyk MA
Urologe A; 2008 Oct; 47(10):1303-10. PubMed ID: 18587556
[TBL] [Abstract][Full Text] [Related]
25. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
26. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
Yu X; Liu F; Zeng L; He F; Zhang R; Yan S; Zeng Z; Shu Y; Zhao C; Wu X; Lei J; Zhang W; Yang C; Wu K; Wu Y; An L; Huang S; Ji X; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Dai Z; Wang X; Liu B; Haydon RC; Luu HH; Gan H; He TC; Chen L
Cell Physiol Biochem; 2018; 47(3):957-971. PubMed ID: 29843133
[TBL] [Abstract][Full Text] [Related]
27. [Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
Miller K; Bergmann L; Doehn C; Gschwend J; Keilholz U
Aktuelle Urol; 2017 Feb; 48(1):72-78. PubMed ID: 28403496
[TBL] [Abstract][Full Text] [Related]
28. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
[No Abstract] [Full Text] [Related]
29. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
[TBL] [Abstract][Full Text] [Related]
31. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
Paule B; Brion N
Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy in Xp11 translocation renal cell carcinoma.
Gomolčáková J; Brezinová B; Dubovan P; Jurišová S; Rejlekova K; Chovanec M; Mardiak J; Mego M
Klin Onkol; 2021; 34(2):137-140. PubMed ID: 33906362
[TBL] [Abstract][Full Text] [Related]
35. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
Kawazoe H; Bilim VN; Ugolkov AV; Yuuki K; Naito S; Nagaoka A; Kato T; Tomita Y
Biochem Biophys Res Commun; 2012 Jul; 423(3):490-5. PubMed ID: 22683636
[TBL] [Abstract][Full Text] [Related]
36. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
[TBL] [Abstract][Full Text] [Related]
37. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Hou MM; Hsieh JJ; Chang NJ; Huang HY; Wang HM; Chuang CK; Hsu T; Chang JW
Clin Drug Investig; 2010; 30(11):799-804. PubMed ID: 20635828
[TBL] [Abstract][Full Text] [Related]
38. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
Gross-Goupil M; Massard C; Ravaud A
Curr Urol Rep; 2012 Feb; 13(1):16-23. PubMed ID: 22139625
[TBL] [Abstract][Full Text] [Related]
40. Optimizing recent advances in metastatic renal cell carcinoma.
Courtney KD; Choueiri TK
Curr Oncol Rep; 2009 May; 11(3):218-26. PubMed ID: 19336014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
